Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc. (NASDAQ:INAB) reported 2024 financial ...

IN8bio announces INB-619, a novel γδ T cell therapy platform targeting CD19, showing promise in B cell depletion with reduced side effects. IN8bio, Inc. has announced the launch of its innovative γδ T ...

IN8bio’s are centered on populating the expansion cohort for the INB-100 trial. The scientific team has met with the FDA in a Type B meeting to help guide the design of the registrational path for INB ...

INB-200 shows significantly improved progression-free survival in glioblastoma patients, with favorable safety profile and no serious toxicities reported. Repeated doses of INB-200 demonstrated an ...

Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp ...

IN8bio (NASDAQ:INAB) stock rose ~110% on Monday after the company reported data from a phase 1 trial of INB-100 in patients with leukemia. The company said that data showed that 100% of evaluable ...

Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trial ...

Indústrias Nucleares do Brasil has signed a contract with Amazônia Azul Technologias de Defesa SA (Amazul) to provide engineering services for the second phase of the uranium enrichment plant at INB's ...

When the doors reopen on the INB Performing Arts Center in November after a six-month renovation, patrons will see new public art, newly accessible seating, a new bar and wider seats. They’ll also ...